RICHMOND: Indivior PLC (Nasdaq/LSE: INDV) announced Tuesday its plans to cancel its secondary listing on the London Stock Exchange, consolidating its primary listing on Nasdaq as the company shifts focus to its U.S. operations. The pharmaceutical firm, known for its addiction treatment SUBLOCADE, said the move reflects its revenue concentration in the U.S., where over…
LONDON: Indivior PLC has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer. The terms of his appointment are subject to, and effective upon, the approval by shareholders of a new remuneration policy at the Company’s AGM in May 2025. Mr. Ciaffoni, 53, was appointed as an Independent Non-Executive…
LONDON, UK: C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announced the execution of an asset purchase agreement for Indivior PLC (LSE: INDV) to acquire the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, C4X_3256 (INDV-2000) for substance use disorder, for £15.95 million. The deal, which terminates the previous license agreement…
RICHMOND: Indivior PLC announced that effective today, the Board of Directors has appointed Mark Crossley as Chief Executive Officer. Shaun Thaxter, in mutual agreement with the Board, is stepping down as Chief Executive Officer and Executive Director. Mr. Crossley has been Chief Financial and Operations Officer (CFOO) and Executive Director of Indivior since February 2017….